Article
Surgery
Cansu Karakas, Ashleigh M. Francis, Min Jin Ha, Hannah F. Wingate, Richard A. Meena, Min Yi, Komal S. Rasaputra, Angelica M. Gutierrez Barrera, Banu Arun, Kim-Anh Do, Aysegul Sahin, Khandan Keyomarsi, Kelly K. Hunt
Summary: The presence of cytoplasmic cyclin E expression in breast cancer patients is associated with a lower rate of pathologic complete response to neoadjuvant chemotherapy and poorer long-term outcomes, making it a potential predictor for treatment response.
Article
Multidisciplinary Sciences
Shuyang Yao, Funda Meric-Bernstam, David Hong, Filip Janku, Aung Naing, Sarina Anne Piha-Paul, Apostolia Maria Tsimberidou, Daniel Karp, Vivek Subbiah, Timothy Anthony Yap, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E. Ileana Dumbrava, Chetna Wathoo, Erick Campbell, Lihou Yu, Yuko Yamamura, Siqing Fu
Summary: This study reviewed the medical records of patients with solid tumors harboring CCNE1 gene amplification and found that CCNE1 amplification is associated with aggressive clinical outcomes in malignancies. The study also showed that anti-angiogenic therapy can improve overall survival in patients receiving gene aberration-related treatment, suggesting the potential of personalized approaches for the treatment of advanced malignancies with CCNE1 amplification.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Aswin Shanmugalingam, Kerry Hitos, Nirmala Pathmanathan, Senarath Edirimmane, T. Michael Hughes, Nicholas K. Ngui
Summary: The study aimed to analyze the concordance between HER2 immunohistochemistry (IHC) and in situ hybridization (ISH) and evaluate the benefit of repeating HER2 testing on the same breast cancer specimens. The results showed perfect positive concordance and agreement between non-equivocal IHC and ISH results, indicating that IHC alone can be reliably used for HER2 status testing based on the 2018 ASCO/CAP guidelines.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Oncology
Tingting Yang, Lihua Kang, Dan Li, Yanqiu Song
Summary: Immunotherapy is a promising treatment for advanced breast cancer, particularly for triple-negative and HER2+ breast cancers. Monoclonal antibodies like trastuzumab, pertuzumab, and T-DM1 have proven effective in treating HER2+ breast cancers and have improved patient survival. Immune checkpoint inhibitors targeting PD-1/PD-L1 have also shown benefits in clinical trials. Adoptive T-cell immunotherapies and tumor vaccines are new approaches that require further study.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Stefania Pianetti, Kathy D. Miller, Hannah H. H. Chen, Sandra Althouse, Sha Cao, Steven J. Michael, Gail E. Sonenshein, Nora D. Mineva
Summary: Breast malignancies are the leading cause of cancer-related death in women. ADAM8 has been identified as a marker of poor survival and a driver of Triple-Negative Breast Cancer growth. A highly specific IHC assay for detecting ADAM8-positive breast tumors has been developed.
CANCER CELL INTERNATIONAL
(2023)
Article
Oncology
Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony D. Elias, Richard D. Carvajal, Thomas J. George, Ying Yuan, Lihou Yu, Shannon N. Westin, Yan Xing, Ecaterina E. Dumbrava, Daniel D. Karp, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Jordi Rodon Ahnert, Naoko Takebe, Karen Lu, Khandan Keyomarsi, Funda Meric-Bernstam
Summary: This study aimed to evaluate the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors. The results showed that adavosertib demonstrated a manageable toxicity profile and promising clinical activity in patients with CCNE1-amplified refractory solid tumors.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jiajie Shi, Liqiu Zhang, Cuizhi Geng
Summary: This study retrospectively analyzed the clinicopathological features and prognosis of 1024 patients with primary breast cancer with ultra-low expression of HER-2, and found that the overall survival rate was higher in the ultra-low expression group compared to the low expression group. Tumor diameter, lymph node metastasis, and Ki67 expression were factors affecting disease-free survival in the ultra-low expression group. Tumor diameter and lymph node metastasis were risk factors affecting overall survival in the ultra-low expression group. Lymph node metastasis and Ki67 expression were risk factors affecting disease-free survival in the low expression group.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Santiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, Marta Tapia, Belen Ortega-Morillo, Ana Lluch, Begona Bermejo, Juan Miguel Cejalvo
Summary: The aim of this review is to study the role of immune response in HER2+ breast cancer, summarize the interaction between the tumor microenvironment and anti-HER2 targeted therapies, and explore the implementation of immune modulators in clinical practice. Understanding the biological aspects of immune response is crucial for developing new treatment strategies.
Article
Biotechnology & Applied Microbiology
Abdul K. Siraj, Sandeep Kumar Parvathareddy, Padmanaban Annaiyappanaidu, Saeeda O. Ahmed, Nabil Siraji, Asma Tulbah, Fouad Al-Dayel, Dahish Ajarim, Khawla S. Al-Kuraya
Summary: The study demonstrated that cyclin D1 over-expression in Middle Eastern breast cancers is associated with favorable prognostic features, serving as an independent predictor of overall survival and recurrence-free survival. Cyclin D1 expression was also found to be associated with phospho-Rb in luminal subtype of breast cancer, predicting luminal A breast cancer independently.
ONCOTARGETS AND THERAPY
(2021)
Review
Oncology
Leopoldo Sitia, Marta Sevieri, Lorena Signati, Arianna Bonizzi, Arianna Chesi, Francesco Mainini, Fabio Corsi, Serena Mazzucchelli
Summary: Breast cancer is a major cause of death in females worldwide, and nanotechnologies have shown significant potential in improving both therapeutic and diagnostic aspects, especially in HER-2-positive breast cancer. This review provides an update on the most promising nanoparticle-based approaches developed in the last decade for HER-2-positive breast cancer therapy and diagnosis.
Article
Chemistry, Analytical
Shayalini Wignarajah, Iva Chianella, Ibtisam E. Tothill
Summary: In this study, two biosensors were developed using gold sensor chips and amperometric detection to detect breast cancer. The sensors relied on sandwich enzyme-linked immunosorbent assays with monoclonal antibodies against HER-1 and HER-2 to capture the biomarkers. The results showed that the sensors had good detection capabilities within the clinical range for HER-1 and HER-2, and the use of gold nanoparticles further enhanced the sensitivity.
Article
Oncology
Shiyuan Zhang, Xiao Yu, Yuting Xiu, Kun Qiao, Cong Jiang, Yuanxi Huang
Summary: HER-2 low expression breast malignant tumors have become a research hotspot, but it is still unclear whether HER-2 low expression represents a special subtype of breast cancer. This study found that HER-2 low expression patients require more effective treatment regimens in the neoadjuvant therapy stage.
Article
Oncology
Angel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Munoz-Mateu, Begon Bermejo, Mireia Margeli Vila, Antonio Anton, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalia Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martin
Summary: In patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer, non-luminal subtype and high CCNE1 expression are associated with resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and poor response to treatment. Furthermore, high levels of the Polo-like kinase 1 (PLK1) mRNA indicate resistance to palbociclib, suggesting that PLK1 may play a role in CDK4/6i resistance. These findings highlight the need for validation of these biomarkers and the exploration of PLK1 as a therapeutic target.
CLINICAL CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Xueqiong Xun, Jun Ai, Fuhui Feng, Pan Hong, Saroj Rai, Ruikang Liu, Baowen Zhang, Yeming Zhou, Huiyong Hu
Summary: This meta-analysis found that the use of Bevacizumab in patients with triple-negative breast cancer and HER-2 negative metastatic breast cancer may increase the incidence of serious adverse events, indicating a need for caution in its usage.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Cell Biology
Binbin Chen, Huimou Chen, Suying Lu, Xiaoqin Zhu, Yi Que, Yu Zhang, Junting Huang, Li Zhang, Yu Zhang, Feifei Sun, Juan Wang, Jia Zhu, Zijun Zhen, Yizhuo Zhang
Summary: Upregulated histone demethylase KDM5B in Ewing sarcoma (EwS) was found to be associated with poor prognosis. KDM5B is involved in regulating the cell cycle pathway and affects the accumulation of CCNE1 protein. Targeting KDM5B with epigenetic drugs could be a potential treatment for EwS.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Kristina Veskimae, Synnove Staff, Francesco Tabaro, Matti Nykter, Jorma Isola, Johanna Maenpaa
GENES CHROMOSOMES & CANCER
(2015)
Letter
Obstetrics & Gynecology
Synnove Staff, Erja Lagerstedt, Janne Seppanen, Johanna Maenpaa
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
(2011)
Letter
Obstetrics & Gynecology
Synnoeve Staff, Jukka Uotila, Helena Tinkanen
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
(2014)
Article
Oncology
Katri Koninki, Mark Barok, Minna Tanner, Synnove Staff, Jukka Pitkanen, Paivikki Hemmila, Joanna Ilvesaro, Jorma Isola
Article
Biochemistry & Molecular Biology
Anni Niskakoski, Sippy Kaur, Synnove Staff, Laura Renkonen-Sinisalo, Heini Lassus, Heikki J. Jarvinen, Jukka-Pekka Mecklin, Ralf Butzow, Paivi Peltomaki
Article
Oncology
Heini Lassus, Synnove Staff, Arto Leminen, Jorma Isola, Ralf Butzow
GYNECOLOGIC ONCOLOGY
(2011)
Correction
Oncology
Heini Lassus, Synnove Staff, Arto Leminen, Jorma Isola, Ralf Butzow
GYNECOLOGIC ONCOLOGY
(2012)
Article
Obstetrics & Gynecology
Synnove Staff, Teemu Tolonen, Satu-Leena Laasanen, Jukka-Pekka Mecklin, Jorma Isola, Johanna Maenpaa
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2014)
Article
Pathology
Synnove Staff, Paula Kujala, Ritva Karhu, Annika Rokman, Joanna Ilvesaro, Saara Kares, Jorma Isola
JOURNAL OF CLINICAL PATHOLOGY
(2013)
Article
Genetics & Heredity
Thorunn Rafnar, Daniel F. Gudbjartsson, Patrick Sulem, Aslaug Jonasdottir, Asgeir Sigurdsson, Adalbjorg Jonasdottir, Soren Besenbacher, Par Lundin, Simon N. Stacey, Julius Gudmundsson, Olafur T. Magnusson, Louise le Roux, Gudbjorg Orlygsdottir, Hafdis T. Helgadottir, Hrefna Johannsdottir, Arnaldur Gylfason, Laufey Tryggvadottir, Jon G. Jonasson, Ana de Juan, Eugenia Ortega, Jose M. Ramon-Cajal, Maria D. Garcia-Prats, Carlos Mayordomo, Angeles Panadero, Fernando Rivera, Katja K. H. Aben, Anne M. van Altena, Leon F. A. G. Massuger, Mervi Aavikko, Paula M. Kujala, Synnove Staff, Lauri A. Aaltonen, Kristrun Olafsdottir, Johannes Bjornsson, Augustine Kong, Anna Salvarsdottir, Hafsteinn Saemundsson, Karl Olafsson, Kristrun R. Benediktsdottir, Jeffrey Gulcher, Gisli Masson, Lambertus A. Kiemeney, Jose I. Mayordomo, Unnur Thorsteinsdottir, Kari Stefansson
Article
Oncology
Synnove Staff, Jorma Isola, Mervi Jumppanen, Minna Tanner
Article
Oncology
Sami K. Saarelainen, Synnove Staff, Nina Peltonen, Terho Lehtimaki, Jorma Isola, Paula M. Kujala, Maarit H. Vuento, Johanna U. Maenpaa
Article
Oncology
S Staff, J Isola, M Tanner
Meeting Abstract
Oncology
S Staff, JJ Isola, M Tanner
CLINICAL CANCER RESEARCH
(2003)